AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...
AbbVie (NYSE:ABBV) said it now expects to report acquired IPR&D and milestone expenses of $1.6B on a pre-tax basis for Q4, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback